Uppsala, Sweden – September 8, 2025 – Orexo (publ.), (STO:ORX) (OTCQX:ORXOY) and its advisory law firms Potter Clarkson LLP and Steptoe LLP have received strong interest for the seminar they will be co-hosting at this year’s Nordic Life Science Days’ conference in Gothenburg, Sweden, on October 13 (invitation published on August 29). However, due to the positive response from those not attending Nordic Life Science Days, the hosts have decided to repeat the event in Stockholm, Sweden, on October 15 at 5:30 pm CEST. The event will take place at Berns Hotel, Spegelsalen, Näckströmsgatan 8, Stockholm.

The seminar will take innovators looking to sell their pharmaceutical or therapeutic inventions in the US ‘behind the curtain’ to find out how the three hosts combined to successfully defend Orexo’s position when they were challenged by heavyweight generic competition. The panel will take the guests through the entire journey, from setting a robust IP strategy to successfully defending their position when Orexo were inevitably challenged by a leading
generic company.
 
Orexo has successfully developed four drugs from concept to market, including Zubsolv® for opioid dependence, which is commercialized by Orexo in the US. The company has extensive experience in building robust patent strategies that support product development cycles. Orexo has demonstrably and repeatedly benefited from these strategies, including when its innovations have been challenged by leading international generic companies, such as Actavis/Teva in 2018 and, more recently, Sun Pharmaceutical Industries in December 2024.

Together, the panel will endeavour to provide the audience with an overview of how to successfully defend their commercial interests not only after, but well before they reach the US market, given that much of the groundwork is typically laid years beforehand. They will then be pleased to answer any questions the audience might have before hosting a short mingle.

Speakers:
• Robert Rönn, SVP and Head of R&D at Orexo; Driving Innovation and Safeguarding Competitiveness through Robust IP Strategies. 
• Stephen McNeeney, Partner and pharmaceutical Patent expert at Potter Clarkson LLP; Partnering for Success - Potter Clarkson’s Role in Orexo’s US Market Achievements 
• John Molenda, Partner at Steptoe LLP, Co-Chair of Steptoe’s Healthcare & Life Sciences Practice; From groundwork to Courtroom Success. 
 
Register here.

For further information contact:
Orexo, Lena Wange, IR and Communications Director, +46 18 780 88 00, ir@orexo.com  
Potter Clarkson LLP, Raina Nadila, Marketing Coordinator, +46 8 505 345 52, raina.nadila@potterclarkson.com 
Steptoe LLP, Vanessa VanderZanden, Business Development Manager, +1 213 439 9450, vvanderzanden@steptoe.com 
 
About Orexo 
Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs.  
On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2024 amounted to SEK 590 million, and the number of employees 110. Orexo is listed on Nasdaq Stockholm's main list and is available as ADRs (ORXOY) on the OTCQX market in the US.  
 
For more information on Orexo, visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube. 
 
About Potter Clarkson LLP 
Leading European intellectual property law firm, Potter Clarkson helps companies, organisations and individuals in the life sciences sector to understand, create, protect and defend the commercial value of their innovations anywhere in the world through IP rights. Recognised as a top tier firm, it is known for its deep technical expertise and clarity of advice. 
 
For more information on Potter Clarkson, visit www.potterclarkson.com and follow us on LinkedIn.  
 
About Steptoe 
In more than 110 years of practice, Steptoe has earned an international reputation for vigorous representation of clients before governmental agencies, successful advocacy in litigation and arbitration, and creative and practical advice in structuring business transactions. Steptoe has more than 500 lawyers and other professional staff across offices in Beijing, Brussels, Chicago, Hong Kong, Houston, London, Los Angeles, New York, San Francisco, and Washington.  
 
For more information, visit www.steptoe.com.